August 7, Dear Mr. Helgerson:
|
|
- Avice Hensley
- 8 years ago
- Views:
Transcription
1 August 7, 2014 Chain Pharmacy Association of New York State New York Chapter, American Society of Consultant Pharmacists New York State Council of Health System Pharmacists Pharmacists Society of the State of New York Mr. Jason Helgerson Deputy Commissioner, Office of Health Insurance Programs Medicaid Director New York State Department of Health Corning Tower Empire State Plaza Albany, NY Dear Mr. Helgerson: We write as a follow-up to the July 28 th stakeholder meeting held by Janet Zachary- Elkind and her team. We were pleased to receive an update following the July meeting stating that you will be participating in the next meeting with pharmacy stakeholders that is scheduled for Monday, August 25 th. July 28 th was the second in a series of meetings scheduled by the Department of Health (DOH) requesting the participation of stakeholders to discuss pharmacy reimbursement policies in the Medicaid program, per language included in the final state budget. Please note that our discussions in these meetings fall within the anti-trust parameters by which association members are bound, namely that discussions around payment methodologies take place at the State s request, and associations and individual participants are prohibited from discussing or referring to individual business decisions. Concerns with DOH s Continued Use of and References to AAC/COD Data The purpose of this letter, as well as the previous letter dated July 15 th, is to highlight and clarify key points of the discussion from stakeholders point of view and to suggest additional topics for the Department s consideration. We view these written communications to be part of the ongoing dialogue and in this context bring your attention to the attached letter dated April 4, 2014 from the National Association of Chain Drug Stores and the National Community Pharmacists Association requesting that the Department discontinue the use of and delete from the DOH website the Average Acquisition Cost (AAC) and Cost of Dispensing (COD) findings in accordance with the adopted state budget. Please note in addition that language authorizing the Department to set generic reimbursement rates was modified in the budget document to include the words: provided that the methodology used by the Department to establish a maximum acquisition cost shall not include average acquisition cost as determined by Department surveys, This statement underscores the legislature s complete rejection of surveys conducted by the Department as the method by which pharmacy reimbursement policies are to be determined.
2 Concerns with DOH s Implied Motivation to Further Cut the State s Pharmacies It is clear that our scheduled stakeholder meetings follow recommendations made in the specific language of the SFY budget. In removing the Department s authority to conduct further surveys, we believe the goal of these meetings is to develop an improved reimbursement methodology that is appropriate and reliable and also budget/cost neutral which does not further cut pharmacy providers. Concerns with DOH s Plan to Apply Reimbursement Developed by Workgroup to Medicaid Managed Care In a similar vein, pharmacy reimbursement mechanisms that we develop jointly should apply only to fee-for-service (FFS). The notion that a new FFS pharmacy reimbursement methodology could be applied to managed care (MC) and thereby provide a rationale for cutting payments to health plans was also firmly rejected during the budget negotiations. In fact, the recent July 18 th announcement by BlueCross BlueShield of Western New York that it will discontinue participation in Medicaid managed care in a number of additional counties suggests that MC payment rates in place today are not sufficient to cover the cost of care. Perhaps more to the point, the amount that health plans receive in premiums has no relationship whatsoever to how pharmacies are paid by pharmacy benefit managers (PBMs) under contract with Medicaid Managed Care plans. Furthermore, the Department has stated that it does not have any information about how pharmacies are paid under Medicaid managed care, and therefore no basis on which to conclude that pharmacies are being over-paid or under-paid. Not only does the Department lack the authority to set payment rates for providers under managed care, it clearly lacks information leading to the logical conclusion that pharmacies could withstand lower payments and continue to dispense the covered medications. The pharmacy claims data to which the Department has access show what health plans pay for the drugs, but not what pharmacies are actually paid. Ironically, the Department mandated full disclosure of all costs from Medicaid FFS pharmacy providers but has stated that it lacks information about costs associated with PBM operations and what pharmacies are actually being paid. Apparently and ironically, despite the Department s quest for transparency in pharmacy pricing, the Department has no interest in determining the actual spread between what it is paying Medicaid Managed Care plans to administer the pharmacy benefit and how much is actually paid to the pharmacy for the actual services to ensure that patients are receiving their medications. Under managed care, two management entities control the flow of the state s Medicaid dollars to pharmacy providers, namely health plans and pharmacy benefit managers. From the discussion at the meeting it appears that nothing is known about additional costs built into the system by PBMs. Does the Department review contracts between PBMs and health plans? Does the Department have access to data showing actual payments made to pharmacies under managed care? These questions could be resolved quite simply: pharmacies participating in Medicaid managed care plans should be paid the same dollar amount that PBMs charge health 2
3 plans for each drug NDC. Such a new policy would create full transparency in the actual cost of the benefit, provided it was well enforced. An additional and important benefit is that any administrative fees paid by health plans to PBMs would not artificially inflate drug costs. As a result the Department could accurately track actual drug spending net of manufacturer rebates. The OBRA 90 rebates were intended to do just that, to bring Medicaid costs to the lowest price point, guaranteed. Such a policy provides a mechanism that reflects the market but does not interfere or constrain. It would not add cost. DOH Pharmaceutical Rebates and Savings Data During the July meeting, DOH staff provided and discussed two charts related to estimated savings from the shift of the overwhelming majority of Medicaid patients to managed care and the estimated manufacturer rebates that the State receives through its prescription drug program. To re-state what was shared with stakeholders, DOH estimates that it saved $470 million for the State Fiscal Year This is the first time that we have seen in writing that the State is saving nearly a half a billion dollars a year from the carve-in of the pharmacy benefit into managed care under Medicaid. Further, when sharing information on how DOH calculated the estimated managed care pharmacy savings it admitted to basing this savings on only one indicator: a 13% increase in the use of generics by Medicaid patients since the shift which has resulted in a 13% decrease in per member per month expenditures. In response, we asked DOH to provide additional data on what other key indicators they can look at beyond generic dispensing which we submit would result in an even greater savings figure than the $470 million cited by DOH. We would respectfully ask that this additional calculation be made prior to the next meeting and such information to be shared with stakeholders at that time. Finally, the State shared that the estimated amount of what the State receives in manufacturer rebates under Medicaid is approximately the same pre- and post-carve in of the pharmacy benefit into managed care. Therefore, approximately 50 cents on every $1 spent by Medicaid for prescription drugs is returned to the State through such rebates. The conclusion we reach from this is that not only is New York saving nearly half a billion dollars per year from the pharmacy carve into managed care but it is continuing to receive nearly the same amount in manufacturer rebates for its drug spend. Based on this we continue to question DOH s motivations to try to further reduce pharmacy reimbursement under Medicaid and to do the same under Medicaid Managed Care when clearly the intended savings from this major shift is being realized by the State. Next Steps By mutual agreement, the agenda for the next stakeholder meeting will include a discussion about pharmacists professional services beyond prescription drug dispensing that are consistent with the Department s overall objective of lowering healthcare costs overall and improving clinical outcomes on an on-going basis. Our intention is to provide models that work in terms of both service and payment structure, including but not limited to medication therapy management, medication adherence and pay for performance. 3
4 As a reminder, at the meeting we also requested written notice indicating when the 0.33% across the board pharmacy reduction would be terminated and whether the elimination of this cut when implemented will be retroactive to April 1, Further, at the Department s request we agreed to research and review possible alternative benchmarks to those currently used by New York Medicaid FFS and make recommendations in this regard at the scheduled September stakeholder meeting. Clarification on AWP and WAC We would also like to take this opportunity to refute some of the Department s negative comments about the reliability of Average Wholesale Price (AWP) and Wholesale Acquisition Cost (WAC) as existing reimbursement benchmarks. In fact, both are widely used in the buying and selling of prescription drugs by State Medicaid programs and commercial plans, they are published and therefore visible and transparent, and, in the case of AWP, always discounted. It must be noted that the 2009 decision of the US District Court for Massachusetts mandated that the value of AWP was to be recalibrated for 8,000 drug products to offset the manipulation by non-pharmacy entities that had been uncovered for 1,356 drugs. As a result, the value of published AWPs was lowered across-the-board by four percentage points effective September 26, 2009 resulting in a significant, immediate decrease in what pharmacies were paid by New York Medicaid (a sizable savings to the program). It is also important to note that for pharmacy stakeholders in New York, 2009 was a watershed year because the court s ruling significantly lowered reimbursement rates in September of 2009 when in April of that same year the budget also changed Medicaid FFS reimbursement from AWP-14% to AWP-16.25% for brand name drugs. In general, what is important about this for the purposes of our recent stakeholder discussions with the Department is that the court ruled that AWP must be a constant 120% of WAC, thereby establishing WAC as the court s own drug pricing benchmark. WAC is defined in federal statute as representative of the manufacturer s list price for a drug to wholesalers or other direct purchasers. In checking the CMS website, for the quarter ending March, states use WAC as the primary or default reimbursement benchmark. WAC is published, used widely and moves with the market. Clarification on Medicaid FFS Brand Name Drug when Less Expansive than Generic Program Finally, during the July meeting we discussed in some detail the current Medicaid FFS policy that maximizes manufacturer rebates by increasing the dispensing rate for certain brands. This policy is beneficial to the state because the net cost of the brand becomes lower than the net cost of the generic. We reviewed forty-one products on the July 3 rd list on the DOH website and found that many have had generic equivalents on the market for some time (i.e. Lovenox, Toprol XL, Wellbutrin and Wellbutrin XL). Relatively few fell 4
5 within the 180-day new to market category. What is important for our discussion is that this Medicaid FFS policy requires pharmacies to carry more costly brand inventory than DOH website and found that many have had generic equivalents on the market for some it would otherwise, thereby increasing their expense burden for FFS Medicaid. The policy could also alter the FFS generic dispensing rate for the individual pharmacy as well as for the Medicaid FFS program. We thank you for considering this additional feedback from the second Stakeholder meeting and again reiterate our appreciation for the time that Janet Zachary-Elkind and her team have committed to these ongoing discussions. We look forward to seeing you on August 25 th and eagerly await written responses to our letters. Sincerely, Michael Duteau R.Ph. President, Chain Pharmacy Association of New York State Kelly Flynn R.Ph. President, NYS chapter of the American Society of Consultant Pharmacists Elizabeth Shlom PharmD, BCPS President, New York State Council of Health-system Pharmacists Charles Catalano R.Ph. President, Pharmacist Society of the State of New York Cc: Acting Health Commissioner Zucker Senate Co-Majority Leader Skelos Senate Co-Majority Leader Klein Senate Democratic Leader Stewart-Cousins Assembly Speaker Silver Assembly Republican Leader Kolb Senate Health Committee Chair Hannon Assembly Health Committee Chair Gottfried 5
An Update on Acquisition Cost Based Reimbursement Models. Jerry Brehany, PharmD, PA-C, JD AVP Pharmacy Services
An Update on Acquisition Cost Based Reimbursement Models Jerry Brehany, PharmD, PA-C, JD AVP Pharmacy Services Agenda Review current prescription drug pricing benchmarks Discuss new Acquisition Cost based
More informationRecommendations for Medicaid Pharmacy Reimbursement for the State of Louisiana
Recommendations for Medicaid Pharmacy Reimbursement for the State of Louisiana Prepared for the Louisiana Department of Health and Hospitals Baton Rouge, Louisiana June 2011 1 Table of Contents I. EXECUTIVE
More informationDrug Price Types and Options for a Future Standard
whitepaper Elsevier / Gold Standard: Drug Price Types and Options for a Future Standard Standardized price information is a vital part of the drug purchasing and reimbursement system. This white paper
More informationIowa Medicaid Enterprise Average Actual Acquisition Cost Reimbursement Frequently Asked Questions
Iowa Medicaid Enterprise Average Actual Acquisition Cost Reimbursement Frequently Asked Questions What are Average Actual Acquisition Cost (AAC) rates? Average Actual Acquisition Cost (AAC) rates are based
More informationHEALTH CENTER REIMBURSEMENT FOR PRESCRIPTION DRUGS: MEDICAID PPS AND SECTION 340B DRUG PRICING CONSIDERATIONS
THE NATIONAL ASSOCIATION OF COMMUNITY HEALTH CENTERS, INC. ISSUE BRIEF # 20 Systems Development Series HEALTH CENTER REIMBURSEMENT FOR PRESCRIPTION DRUGS: MEDICAID PPS AND SECTION 340B DRUG PRICING CONSIDERATIONS
More informationSHINING THE LIGHT ON NON-TRANSPARENT PBM CASH FLOWS
SHINING THE LIGHT ON NON-TRANSPARENT PBM CASH FLOWS By Robert I. Garis, Ph.D.; Bartholomew E. Clark, Ph.D.; and Mark V. Siracuse, Ph.D. ILLUSTRATION: STEPHANIE CARTER An overview to assist pharmacists
More informationOverview of Drug Pricing for Public Programs
Overview of Drug Pricing for Public Programs 1 J U L I E C R O S S, I N D E P E N D E N T C O N S U L T A N T A N N E D O N N E L L Y, P R O J E C T I N F O R M A N D F A I R P R I C I N G C O A L I T
More informationRebates and Discounts on Physician-Administered Drugs. Medicaid Program Department of Health
New York State Office of the State Comptroller Thomas P. DiNapoli Division of State Government Accountability Rebates and Discounts on Physician-Administered Drugs Medicaid Program Department of Health
More informationCOMPARING PHARMACY REIMBURSEMENT: MEDICARE PART D TO MEDICAID
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL COMPARING PHARMACY REIMBURSEMENT: MEDICARE PART D TO MEDICAID Daniel R. Levinson Inspector General February 2009 Office of Inspector
More informationSMAC represents the ceiling price that the program is going to reimburse for generics and is determined by:
Maryland Generic PDL Analysis October 2012 Maryland Generic PDL Analysis Introduction Upon request by the Maryland Department of Health and Mental Hygiene, Magellan Medicaid Administration has completed
More informationPharmacy Benefit Managers
Pharmacy Benefit Managers And the need for fair and reasonable standards over the practice of auditing pharmacies SB 175 Establishes Procedures & Guidelines for the Auditing of Pharmacy Records & Requires
More informationThe Impact of Recent Medicare and Medicaid Cuts on Patients Access to Independent Community Pharmacies
The Impact of Recent Medicare and Medicaid Cuts on Patients Access to Independent Community Pharmacies Independent Pharmacies are Important Primary Care Providers in Rural Communities: For Medicare and
More informationMedical Care Advisory Committee. Andy Vasquez, Deputy Director, Medicaid/CHIP Vendor Drug Program Health and Human Services Commission
TO: Medical Care Advisory Committee DATE: November 8, 2013 FROM: Andy Vasquez, Deputy Director, Medicaid/CHIP Vendor Drug Program Health and Human Services Commission Agenda Item No.: 7 SUBJECT: Fee-for-Service
More informationPrescription Drug Pricing
Prescription Drug Pricing Anna Cook Julie Somers Julia Christensen Congressional Budget Office January 30, 2009 Manufacturers Shipments of Drugs Through the Supply Chain Key Prices in the Pharmaceutical
More informationTEXAS MEDICAID: THE IMPACT OF MANAGED CARE ON MEDICAID RECIPIENTS INDEPENDENT PHARMACIES
TEXAS MEDICAID: THE IMPACT OF MANAGED CARE ON MEDICAID RECIPIENTS INDEPENDENT PHARMACIES A white paper evaluating the transition of the Prescription Drug Benefit into Medicaid Managed Care. Page 1 Executive
More informationPursuant to the authority vested in the Commissioner of Health by Article 33 of the
Electronic Prescriptions and Records for Hypodermic Needles and Hypodermic Syringes Effective date: 10/9/13 Pursuant to the authority vested in the Commissioner of Health by Article 33 of the Public Health
More informationSTATES COLLECTION OF REBATES FOR DRUGS PAID THROUGH MEDICAID MANAGED CARE ORGANIZATIONS
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL STATES COLLECTION OF REBATES FOR DRUGS PAID THROUGH MEDICAID MANAGED CARE ORGANIZATIONS Daniel R. Levinson Inspector General September
More information340B Drug Discount Program Overview and Emerging Issues
340B Drug Discount Program Overview and Emerging Issues I. APPLICABLE STATUTE AND OTHER LEGAL AUTHORITIES Section 340B of the Public Health Service Act (42 U.S.C. 256b) requires pharmaceutical manufacturers,
More informationSupply Chain Management Professional Education Review
Supply Chain Management Professional Education Review A monthly e Newsletter by the Department of Supply Chain Management and Marketing Sciences June 2009 In this month s issue Increasing profits will
More information10/1/2013. Objectives. 340B Drug Pricing Program; Transitioning from Access to Integrity. 340B Stats, Arkansas. 340B Participating Entities, AR
Objectives Drug Pricing Program; Transitioning from Access to Integrity Arkansas Association of Health-system Pharmacists 47 th Annual Fall Seminar October 3 & 4, 2013 Chris Hatwig RPh, MS, FASHP President,
More informationPharmacy Benefit Managers: What we do
Pharmacy Benefit Managers: What we do Steve Boekenoogen, Pharm.D. Poulsbo, WA & San Diego CA Manager, Clinical Services & Integration MedImpact Healthcare Systems, Inc Dan Danielson, M.S., RPh. Lynnwood,
More informationPrescription-drug expenditures are one of
Effective Contracting with Pharmacy Benefit Managers: Protecting a plan sponsor s resources by Brian N. Anderson and Robert Cosway 20% 19% 18% 17% 16% 15% 14% 13% 12% 11% 10% 9% 8% 7% 6% 5% 4% 3% 2% 1%
More informationOFFICE OF INSPECTOR GENERAL
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL Cost Containment of Medicaid HIV/AIDS Drug Expenditures JULY 2001 OEI-05-99-00611 OFFICE OF INSPECTOR GENERAL The mission of the Office
More informationReimbursement Update: Market Changes and Proposed AMP Regulations
Reimbursement Update: Market Changes and Proposed AMP Regulations Emdeon All Customer Meeting September 14, 2012 Tim Kosty, RPh, MBA PHSI Background & Experience Pharmacist based consulting practice since
More informationOur pharmacy, medical/surgical and capital equipment catalogs with over 550,000 line items.
Our pharmacy, medical/surgical and capital equipment catalogs with over 550,000 line items. Pharmacy: Our online pharmacy catalog offers you a comprehensive product choice of more than 25,000 SKU line
More informationThe Basics of Pharmacy Benefits Management (PBM) 2009
The Basics of Pharmacy Benefits Management (PBM) 2009 Andrew Kingery Pharmacy Account Management Virginia CE Forum 2009 Course# 201719 Objectives & Introduction Provide basic components of a PBM Define
More informationWHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain
WHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing
More informationSettlement Impact on AWP Drug Pricing for Payors, Pharmacies, PBMs, and Consumers
Settlement Impact on AWP Drug Pricing for Payors, Pharmacies, PBMs, and Consumers Co-sponsored by the Life Sciences and Payors, Plans, and Managed Care Practice Groups Tuesday, November 3, 2009 1:00-2:30
More informationJanuary 4, 2008. Richard M. Daines, M.D. Commissioner Department of Health Corning Tower Empire State Plaza Albany, NY 12237.
THOMAS P. DiNAPOLI STATE COMPTROLLER 110 STATE STREET ALBANY, NEW YORK 12236 STATE OF NEW YORK OFFICE OF THE STATE COMPTROLLER January 4, 2008 Richard M. Daines, M.D. Commissioner Department of Health
More informationState Pharmacy Assistance Programs at a Crossroads:
State Pharmacy Assistance Programs at a Crossroads: How Will They Respond to the Medicare Drug Benefit? By Claudia Williams, Sarah Goodell, Jack Hoadley, Ellen O Brien, and Matt Kanter* July 2005 This
More informationMaryland Medicaid Program
Maryland Medicaid Program Maryland s Pharmacy Discount Waiver Tuesday, November 19, 2002 Debbie I. Chang Deputy Secretary for Health Care Financing Maryland Department of Health and Mental Hygiene Overview
More informationARRANGEMENTS FOR THE FUTURE SUPPLY AND REIMBURSEMENT OF GENERIC MEDICINES FOR NHS SCOTLAND. Consultation Document
ARRANGEMENTS FOR THE FUTURE SUPPLY AND REIMBURSEMENT OF GENERIC MEDICINES FOR NHS SCOTLAND Consultation Document Scottish Executive Health Department October 2003 Arrangements For The Future Supply And
More informationWhen Public Payment Declines, Does Cost-Shifting Occur? Hospital and Physician Responses. November 13, 2002 Washington, DC
When Public Payment Declines, Does Cost-Shifting Occur? Hospital and Physician Responses November 13, 2002 Washington, DC These materials were commissioned by the Robert Wood Johnson Foundation for use
More informationPrescription drug costs continue to rise at
Prescription Drugs Developing an Effective Generic Prescription Drug Program by John D. Jones Pharmacy benefit managers (PBMs) use a variety of pricing strategies. When employers have a thorough knowledge
More informationDC DEPARTMENT OF HEALTH Pharmaceutical Procurement and Distribution Pharmaceutical Warehouse. DC Health Care Safety Net ALLIANCE PROGRAM
DC DEPARTMENT OF HEALTH Pharmaceutical Warehouse DC Health Care Safety Net ALLIANCE PROGRAM OPERATIONAL PROTOCOLS Operational protocols for the DC Health Care Alliance program through the DOH Pharmaceutical
More informationReimbursement for Physician- Administered Drugs:
Reimbursement for Physician- Purchased and Physician- Administered Drugs: Understanding the Buy and Bill Process 60889-R5-V1 This information is provided d for your background education and is not intended
More informationCONGRESS OF THE UNITED STATES CONGRESSIONAL BUDGET OFFICE
CONGRESS OF THE UNITED STATES CONGRESSIONAL BUDGET OFFICE A CBO PAPER DECEMBER 2004 Medicaid s Reimbursements to Pharmacies for Prescription Drugs A CBO PAPER Medicaid s Reimbursements to Pharmacies for
More information-1058- BEFORE THE DEPARTMENT OF PUBLIC HEALTH AND HUMAN SERVICES OF THE STATE OF MONTANA ) ) ) ) )
-1058- BEFORE THE DEPARTMENT OF PUBLIC HEALTH AND HUMAN SERVICES OF THE STATE OF MONTANA In the matter of the amendment of ARM 37.85.104 and 37.85.105 pertaining to the revision of fee schedules for Medicaid
More informationHot Topics in Medicaid
Hot Topics in Medicaid Chad Hope, Pharm.D. Pharmacy Program Manager DHSS/DHCS chad.hope@alaska.gov; 907-334-2654 ***These slides had to be submitted in December 2014 and may contain outdated information***
More informationNAMD WORKING PAPER SERIES. Medicaid and the 340B Program: Alignment and Modernization Opportunities
NAMD WORKING PAPER SERIES Medicaid and the 340B Program: Alignment and Modernization Opportunities May 2015 444 North Capitol Street, Suite 524 Washington, DC 20001 Phone: 202.403.8620 www.medicaiddirectors.org
More informationReal-time Pre and Post Claim Edits: Improve Reimbursement, Compliance and Safety
Real-time Pre and Post Claim Edits: Improve Reimbursement, Compliance and Safety An ESI Healthcare Business Solutions White Paper by Thomas Renshaw R.Ph. Introduction Outpatient pharmacies submitting claims
More informationEffectively Managing a Medicaid Pharmacy Benefit Program
Effectively Managing a Medicaid Pharmacy Benefit Program Background The National Community Pharmacists Association (NCPA) has developed this document to provide guidance to association executives, staff,
More informationPrinted copies are for reference only. Please refer to the electronic copy of this policy for the latest version.
340B Pharmacy Audit Policy Version: 1.4 Date Created: 01/05/2015 Date Approved: 02/18/2015 Printed copies are for reference only. Please refer to the electronic copy of this policy for the latest version.
More informationLICENSING COMMITTEE AD-HOC Committee on Pharmaceutical Benefit Managers (PBMs) Regulation. Meeting Summary
California State Board of Pharmacy STATE AND CONSUMER SERVICES AGENCY 400 R Street, Suite 4070, Sacramento, CA 95814-6237 DEPARTMENT OF CONSUMER AFFAIRS Phone (916) 445-5014 GRAY DAVIS, GOVERNOR Fax (916)
More informationADAP and Insurance: Purchasing/Continuing Insurance and Utilizing Pharmacy Benefits Managers/Insurance Benefits Managers
ADAP and Insurance: Purchasing/Continuing Insurance and Utilizing Pharmacy Benefits Managers/Insurance Benefits Managers Amy Killelea and Britten Pund, NASTAD June 12, 2013 Agenda Overview of ADAPs ability
More informationPrepared By: The Professional Staff of the Committee on Banking and Insurance REVISED:
BILL: SB 860 The Florida Senate BILL ANALYSIS AND FISCAL IMPACT STATEMENT (This document is based on the provisions contained in the legislation as of the latest date listed below.) Prepared By: The Professional
More informationEmpire BlueCross BlueShield
O f f i c e o f t h e N e w Y o r k S t a t e C o m p t r o l l e r Division of State Government Accountability Empire BlueCross BlueShield New York State Health Insurance Program Payments Made to Albany
More informationNuts and Bolts of Pharmacy Reimbursement: Why It Should Matter To You
Nuts and Bolts of Pharmacy Reimbursement: Why It Should Matter To You By Lisa L. Causey, J.D., LL.M. Candidate lisalcausey@comcast.net Spending in the United States for prescription drugs was $216.7 billion
More information340B Drug Pricing Program
340B Drug Pricing Program Chad E. Gay Director of Contract Compliance Agenda Discuss the 340B drug pricing program How the program is defined Who is eligible Enrollment Dates to be aware of Source Documentation
More informationSTATE 340B MEDICAID BILLING BEST PRACTICES
Safety Net Hospitals for Pharmaceutical Access STATE 340B MEDICAID BILLING BEST PRACTICES State Medicaid program shared savings arrangements with 340B providers take various forms, including: (1) enhanced
More informationImpact of Health Reform on Prescription Drugs
Impact of Health Reform on Prescription Drugs 1 Indirect Effects Increased Rx Volume = More Prescriptions! Page 2 Retiree Drug Subsidy (RDS) Before HCR Tax-Free Subsidy RDS as taxdeductible income After
More informationMedicaid Claims Processing Activity April 1, 2012 through September 30, 2012 Medicaid Program Department of Health
New York State Office of the State Comptroller Thomas P. DiNapoli Division of State Government Accountability Medicaid Claims Processing Activity April 1, 2012 through September 30, 2012 Medicaid Program
More informationFinally... maybe? The Long Awaited 340B Mega Guidance. Georgia Healthcare Financial Management Association. October 2015
Finally... maybe? The Long Awaited 340B Mega Guidance Georgia Healthcare Financial Management Association October 2015 Disclaimer This webinar assumes the participant is familiar with the basic operations
More informationASHP Regulatory Alert
Proposed Guidance: 340B Drug Discount Program Introduction On Friday, August 28, 2015, the Health Resources and Services Administration (HRSA) published the long awaited proposed omnibus guidance for the
More informationMedicare Coverage Gap Discount Program Dispute Resolution
DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, Maryland 21244-1850 CENTER FOR MEDICARE DATE: March 5, 2012 TO: FROM: SUBJECT: Pharmaceutical
More informationMedicaid Payments Made Pursuant to Medicare Part C. Medicaid Program Department of Health
New York State Office of the State Comptroller Thomas P. DiNapoli Division of State Government Accountability Medicaid Payments Made Pursuant to Medicare Part C Medicaid Program Department of Health Report
More informationAn Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit
An Evaluation of Specialty Drug Pricing Under the Pharmacy and Medical Benefit March 2014 PREPARED BY Brenda Motheral, MBA, PhD President Corey Belken, PharmD Vice President Artemetrx Specialty Drug Solutions
More informationImproper Payments to a Physical Therapist. Medicaid Program Department of Health
New York State Office of the State Comptroller Thomas P. DiNapoli Division of State Government Accountability Improper Payments to a Physical Therapist Medicaid Program Department of Health Report 2013-S-15
More informationNatalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services. CVS Caremark Corporation
Prepared Statement of Natalie Pons, Senior Vice President, Assistant General Counsel, Health Care Services CVS Caremark Corporation Before the Subcommittee on Regulatory Reform, Commercial and Antitrust
More informationThe 3 Keys to Success in Your 340B Program. Rob Nahoopii, PharmD, MS, BCPS CEO Turnkey Pharmacy Solutions A 340B Management Company
The 3 Keys to Success in Your 340B Program Rob Nahoopii, PharmD, MS, BCPS CEO Turnkey Pharmacy Solutions A 340B Management Company Objectives Provide a description and overview of the 340B program Discuss
More informationTEXAS VENDOR DRUG PROGRAM PHARMACY PROVIDER PROCEDURE MANUAL
1 OF 10 DOCUMENT HISTORY LOG STATUS REVISION EFFECTIVE DESCRIPTION Revision 1.1 Sep. 1, 2015 Baseline 1.0 Feb. 1, 2015 3.1 Eligible Entity 5 CAD Claim Submission o Instruction update and email address.
More informationPrescription Drugs. Inside this Brief. Background Brief on. Spending for Prescription Drugs. Medicare and. Prescription Drugs. State Discount Programs
Background Brief on September 2014 Inside this Brief Spending for Prescription Drugs Medicare and Prescription Drugs State Discount Programs Discount Cards and Assistance Programs Oregon Prescription Drug
More informationOIG Responses to Additional Questions from Chairman Pitts Regarding the 340B Program May 4, 2015
OIG Responses to Additional Questions from Chairman Pitts Regarding the 340B Program May 4, 2015 1. HRSA had been preparing a regulation to address the definition of a patient and hospital eligibility,
More informationPBM Revenue Generation Secrets HEALTHCARE ANALYTICS
PBM Revenue Generation Secrets HEALTHCARE ANALYTICS TODAY S AGENDA Brief background on the Prescription Benefits Manager (PBM) marketplace Basic Components of a PBM Contract How PBMs are exploiting contract
More informationPrescription Drugs. Inside this Brief. Background Brief on
Background Brief on Prescription Drugs Prepared by: Rick Berkobien Inside this Brief November 2006 Spending for Prescription Drugs Medicare and Prescription Drugs Drug Costs in Other Countries and the
More informationDepartment of Civil Service
O FFICE OF THE NEW YORK STATE COMPTROLLER DIVISION OF STATE GOVERNMENT ACCOUNTABILITY Department of Civil Service Management of the Health Insurance Fund Balance Report 2009-S-48 Thomas P. DiNapoli Table
More informationWorkers Compensation Medical Services Review Committee Meeting Minutes November 7, 2014
Workers Compensation Medical Services Review Committee Meeting Minutes November 7, 2014 I. Call to order Director Monagle, acting as Chair of the Medical Services Review Committee, called the Committee
More informationLegal Alert. Long-Awaited 340B Program Guidance Now Available for Comments: What Stakeholders Need to Know. Authors
September 10, 2015 1 Legal Alert Authors Stephanie Trunk Partner stephanie.trunk@arentfox.com Erin E. Atkins Associate erin.atkins@arentfox.com Long-Awaited 340B Program Guidance Now Available for Comments:
More informationPredictive Acquisition
Predictive Acquisition Cost q Introduction to PAC Aprili 2013 Agenda Five key criteria for new price type Five key criteria for new price type What is PAC? Key milestones since launch Use cases across
More information340B Drug Discount Program Identifying risks and internal audit focus areas
340B Drug Discount Program Identifying risks and internal audit focus areas Introduction The 340B Drug Discount Program is administered by the Health Resources and Services Administration (HRSA) Office
More informationEnclosure A DEFINITIONS
Enclosure A REBATE AGREEMENT Between The Secretary of Health and Human Services (hereinafter referred to as "the Secretary") and The Manufacturer Identified in Section XI of this Agreement (hereinafter
More informationOhio s Care Coordination Program A Proven Opportunity for a new way in Ohio s Medicaid Program
Ohio s Care Coordination Program A Proven Opportunity for a new way in Ohio s Medicaid Program Ohio s Status Quo: The economy and reliance on one time funding has led to an $8 billion shortfall State expenditures
More informationNACHC ANALYSIS: Establishing and Collecting Fees for Health Center Services. July, 2009
NACHC ANALYSIS: Establishing and Collecting Fees for Health Center Services July, 2009 Prepared for NACHC by: Michael Glomb Feldesman, Tucker, Leifer, Fidell 2001 L Street, N.W. (202)466-8960 mglomb@feldesmantucker.com
More informationCalifornia Primary Care Association 2012 New CFO Boot Camp
California Primary Care Association 2012 New CFO Boot Camp Medi-Cal FQHC PPS, Medicare FQHC, and Other Revenue/Reimbursement Strategies for Health Centers Presented by: Michael B. Schnake, CPA, CGFM Presentation
More informationMEDICAID DRUG PRICE COMPARISON: AVERAGE SALES PRICE TO AVERAGE WHOLESALE PRICE
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL MEDICAID DRUG PRICE COMPARISON: AVERAGE SALES PRICE TO AVERAGE WHOLESALE PRICE Daniel R. Levinson Inspector General June 2005 OEI-03-05-00200
More informationHB 686-FN-A - AS INTRODUCED. establishing a single payer health care system and making an appropriation therefor.
0 SESSION -0 0/0 HOUSE BILL AN ACT -FN-A establishing a single payer health care system and making an appropriation therefor. SPONSORS: Rep. McNamara, Hills ; Rep. Suzanne Smith, Graf ; Rep. Moody, Rock
More informationNovember 4, 2010. Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington, DC 20515.
CONGRESSIONAL BUDGET OFFICE U.S. Congress Washington, DC 20515 Douglas W. Elmendorf, Director November 4, 2010 Honorable Paul Ryan Ranking Member Committee on the Budget U.S. House of Representatives Washington,
More informationThe Unintended Consequences of Restrictions on the Use of Maximum Allowable Cost Programs ( MACs ) for Pharmacy Reimbursement
The Unintended Consequences of Restrictions on the Use of Maximum Allowable Cost Programs ( MACs ) for Pharmacy Reimbursement David A. Hyman H. Ross & Helen Workman Chair in Law Professor of Medicine University
More informationPharmaceutical Marketplace Dynamics Expenditures, Distribution, Coverage, Pricing
Pharmaceutical Marketplace Dynamics Expenditures, Distribution, Coverage, Pricing John M. Coster, Ph.D., R.Ph. National Association of Chain Drug Stores Presented at National Health Policy Forum Session,
More information340B Drug Pricing Program January 15, 2015
340B Drug Pricing Program January 15, 2015 340B Basics - Gary Merchant. MBA, BSPharm 340B Audit - Robert Theriault, MBA, BSPharm Declarations Neither Gary Merchant nor Robert Theriault have no actual or
More informationCompPharma. Manage. Process. Inform. Ensure. The Role of a PBM in Workers Compensation
Manage Inform Process Ensure The Role of a PBM in Workers Compensation Understanding the role of workers compensation pharmacy benefit managers (WC-PBMs) can help state and local government agencies ensure
More informationMedicare Compliance, Fraud, Waste and Abuse Training for Medicare Part D- Contracted Pharmacies
Medicare Compliance, Fraud, Waste and Abuse Training for Medicare Part D- Contracted Pharmacies 2008 Medco Health Solutions, Inc. All rights reserved. Training Introduction In this training, you ll learn
More informationMedicaid Claims Processing Activity April 1, 2014 Through September 30, 2014 Medicaid Program Department of Health
New York State Office of the State Comptroller Thomas P. DiNapoli Division of State Government Accountability Medicaid Claims Processing Activity April 1, 2014 Through September 30, 2014 Medicaid Program
More informationPrescription drugs are a critical component of health care. Because of the role of drugs in treating conditions, it is important that Medicare ensures that its beneficiaries have access to appropriate
More information(RIN) 0906-AB08; 340-B
October, 2015 Ms. Krista Pedley Director, Office of Pharmacy Affairs (OPA) Health Resources and Services Administration (HRSA) 5600 Fishers Lane, Mail Stop 08W05A Rockville, Maryland 20857 Re: Regulatory
More information340B Drug Pricing Program. A Survey of the Program s Past, Present, and Future
340B Drug Pricing Program A Survey of the Program s Past, Present, and Future Presented by: Daniel Soldato Wyatt, Tarrant & Combs LLP dsoldato@wyattfirm.com (859) 288-7631 Disclaimer The views expressed
More informationHRSA Pharmacy Services Support Center: The 340B Access Resource
HRSA Pharmacy Services Support Center: The 340B Access Resource Lisa Scholz PharmD, MBA Vice President, APhA HRSA Pharmacy Services Support Center Office of Population Affairs Webinar 9/16 INTEGRITY ACCESS
More informationP.L.2015, CHAPTER 179, approved January 11, 2016 Senate, No. 2301 (First Reprint)
Title B. Subtitle. Chapter F. (New) "Pharmacy Benefits Managers" - - C.B:F- to B:F- - Note P.L.0, CHAPTER, approved January, 0 Senate, No. 0 (First Reprint) 0 0 0 AN ACT concerning pharmacy benefits managers
More informationDepartment of Mental Health
332401 Forensic Services $4,319,519 $4,328,547 $4,371,610 $4,323,287 $3,089,969 $3,244,251 0.2% 1.0% -1.1% -28.5% 5.0% Section 335.10.10 of Am. Sub. H.B. 1 of the 128th G.A. (originally established by
More informationTABLE OF CONTENTS - RI Comprehensive Health Insurance Legislation
TABLE OF CONTENTS - RI Comprehensive Health Insurance Legislation 23-93-1. Purpose. 23-93-2. Definitions. 23-93-3. Rhode Island Comprehensive Health Insurance Program. (a) Organization. (b) Director. 23-93-4.
More information340B Drug Discount Program 2013 March 15, 2013 1 Agenda 340B Program Overview Covered Entities Covered Drugs Covered Patients Why HRSA Audits How to Prepare for HRSA Audit Questions/Answers 2 340 DRUG
More informationA BILL. To provide a single, universal, comprehensive health insurance benefit for all residents of Illinois, and for other purposes.
Synopsis: This bill expands comprehensive health coverage to all Illinois residents using a single-payer statewide insurance system. Doctors and hospitals remain private, and patients retain their choice
More informationOctober 27, 2015. Attention: RIN 0906-AB08. RE: 340B Drug Pricing Program Omnibus Guidance. Dear Captain Pedley:
Captain Krista Pedley, Director Office of Pharmacy Affairs Health Resources and Services Administration 5600 Fishers Lane Mail Stop 08W05A Rockville, MD 20857 Attention: RIN 0906-AB08 RE: 340B Drug Pricing
More informationTestimony of Patrick J. O Connell Chief, Civil Medicaid Fraud Section Office of the Attorney General of Texas
Testimony of Patrick J. O Connell Chief, Civil Medicaid Fraud Section Office of the Attorney General of Texas Mr. Chairman and members of the Committee: Good morning. My name is Patrick O Connell. I am
More informationUpdate on Medicare Part D: 2009 and Beyond
Update on Medicare Part D: 2009 and Beyond 2009 NACDS Pharmacy & Technology Conference Christine C. Rinn Donald L. Bell, II Outline of Presentation» Introduction/Background on Part D» Trends in Part D»
More informationAffordable Care Act (ACA) Health Insurance Exchanges and Medicaid Expansion
Affordable Care Act (ACA) Health Insurance Exchanges and Medicaid Expansion Table of Contents Expanded Coverage... 2 Health Insurance Exchanges... 3 Medicaid Expansion... 8 Novartis Pharmaceuticals Corporation
More informationOREGON DID NOT BILL MANUFACTURERS FOR REBATES FOR PHYSICIAN-ADMINISTERED DRUGS DISPENSED TO ENROLLEES OF MEDICAID MANAGED-CARE ORGANIZATIONS
Department of Health and Human Services OFFICE OF INSPECTOR GENERAL OREGON DID NOT BILL MANUFACTURERS FOR REBATES FOR PHYSICIAN-ADMINISTERED DRUGS DISPENSED TO ENROLLEES OF MEDICAID MANAGED-CARE ORGANIZATIONS
More informationPublic Authority Debt Structure and New York s Future Generations
Public Authority Debt Structure and New York s Future Generations September 2010 Thomas P. DiNapoli New York State Comptroller Additional copies of this report may be obtained from: Office of the State
More informationControlled Substances Prescription Monitoring Program. Dean Wright, RPh Arizona State Board of Pharmacy
Controlled Substances Prescription Monitoring Program Dean Wright, RPh Arizona State Board of Pharmacy Controlled Substances Prescription Monitoring Program Arizona s Forty-eighth Legislature passed H.B.
More informationKeep Your Savings: 340B Audits and Ensuring Compliance
Keep Your Savings: 340B Audits and Ensuring Compliance Disclosure This presentation reflects experience with the topics at hand and does not constitute legal advice, and does not reflect interpretation
More information